Pfizer (PFE) Q3 2026 Earnings
Adjusted results include a one-time $650 million Acquired In-Process R&D charge related to the Innovent Biologics in-licensing and collaboration agreement (approximately $0.10 unfavorable impact). GAAP diluted EPS of $0.56 additionally reflects $1,128 million amortization of intangible assets and $791 million restructuring charges and certain acquisition-related costs.
How Did PFE Stock React to Q3 2026 Earnings?
Did PFE Beat Earnings? Q3 2026 Results
Yes. Pfizer reported Q3 2026 earnings of $0.87 a share on Nov 3, 2026, beating the $0.73 consensus estimate by 19.5%. Revenue was $16.6B against a $15.9B estimate.
Pfizer delivered a strong third-quarter beat, posting adjusted EPS of $0.87 against the $0.73 consensus estimate, a 19.51% positive surprise that extended the drugmaker's streak of beating EPS expectations to seven consecutive quarters. Revenue of $16.58 billion edged past the $15.88 billion forecast by 4.45%, even as total sales slipped 0.4% year-over-year, held back by a $771 million, or 63%, collapse in Paxlovid on lower COVID-19 infection rates and a $339 million decline in Comirnaty. The real story was elsewhere: stripping out those two COVID products, Pfizer's portfolio grew 7% operationally, with recently launched and acquired medicines surging 32% operationally, led by Eliquis, Padcev, and the Vyndaqel family. Shares have been trading near multi-year highs as investors focus on the company's oncology and obesity pipeline momentum. Encouraged by that underlying strength, management raised full-year 2026 revenue guidance to $62.00 billion to $64.00 billion and lifted adjusted diluted EPS guidance to $2.95 to $3.05, even after absorbing roughly $0.10 from a $650 million Innovent Biologics in-licensing charge.
- Eliquis up $513 million (25% operationally) on higher U.S. net price from lower rebates and channel mix plus higher global demand
- Padcev up $255 million (55%) on first-line la/mUC share gains and muscle-invasive bladder cancer launch
- Vyndaqel family up $193 million (12%) on U.S. market expansion and international diagnosis uptake
- Nurtec ODT/Vydura up $135 million (33%) on U.S. demand and international launches
- Lorbrena up $114 million (43%) on first-line ALK+ mNSCLC patient share gains
- Paxlovid down $771 million (63%) on lower COVID-19 infections
- Comirnaty down $339 million (29%) on lower U.S. returns provision adjustment and narrower vaccine recommendations
- Prevnar family down $180 million (10%) on lower vaccination rates and adult share erosion
- Launched and acquired products grew 32% operationally; non-COVID revenues grew 7% operationally
- R&D expenses up 18% operationally on oncology and obesity spending
“Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value. Our obesity program continued to advance and recent milestones in oncology, immunology and vaccines further demonstrate the potential of our pipeline. With a robust slate of expected catalysts ahead, I believe we're well positioned to deliver meaningful new medicines for patients and lasting value in the years ahead.”
Pfizer CEO, on the earnings call
What Is Pfizer's Outlook?
Pfizer raised full-year 2026 guidance: - **Revenue:** $62.0 to $64.0 billion, up from $60.5 to $62.5 billion. - **Adjusted diluted EPS:** raised and narrowed to $2.95 to $3.05, from $2.80 to $3.00. This includes an approximately $0.10 unfavorable impact from the $650 million Innovent Acquired IPR&D charge. - **Adjusted SI&A expenses:** $12.5 to $13.5 billion. - **Adjusted R&D expenses:** raised to $10.8 to $11.8 billion, from $10.5 to $11.5 billion. - **Adjusted effective tax rate:** approximately 15.0%. Guidance assumes: - An approximately $1.1 billion unfavorable revenue impact from generic and biosimilar competition. - No business development transactions not yet completed. - About 5.74 billion diluted shares. - No share repurchases in 2026. The company expects to continue de-levering over the longer term.
PFE YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $16.6B | $16.7B | −0.4% |
| Net Income | $3.2B | $3.5B | −8.4% |
PFE Revenue by Segment
PFE Revenue by Geography
When Does Pfizer Report Next?
Figures from SEC filings and company reports. Not investment advice.